References
- Information Services Division ScotlandChronic obstructive pulmonary disease (COPD)2013 Available from: http://www.isdscotland.org/Health-Topics/General-Practice/GP-Consultations/Health-Conditions/COPDAccessed May 13, 2016
- Audit ScotlandManaging Long-Term ConditionsEdinburghAudit Scotland2007 Available from: http://www.audit-scotland.gov.uk/docs/health/2007/nr_070816_managing_long_term.pdfAccessed May 13, 2016
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of COPDBethesda (MD)GOLD2014
- van der MolenTMiravitllesMKocksJWCOPD management: role of symptom assessment in routine clinical practiceInt J Chron Obstruct Pulmon Dis2013846147124143085
- AlmirallSALong-term efficacy and safety of aclidinium/formoterol fixed-dose combination Available from: https://clinicaltrials.gov/ct2/show/NCT01462942. NLM identifier: NCT01462942Accessed May 13, 2016
- Forest LaboratoriesEfficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC) Available from: https://clinicaltrials.gov/ct2/show/NCT01437397. NLM identifier: NCT01437397Accessed May 13, 2016
- European Medicines AgencyDuaklir Genuair Assessement report2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003745/WC500178415.pdfAcessed May 30, 2016
- BatemanEDChapmanKRSinghDAclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)Respir Res2015169226233481
- Gruffydd-JonesKJonesMMNICE guidelines for chronic obstructive pulmonary disease: implications for primary careBr J Gen Pract201161583919221276335
- KarabisAMocarskiMEijgelshovenIBergmanGEconomic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 yearsClinicoecon Outcomes Res2014617518524741321
- SamyshkinYKotchieRWMörkACBriggsAHBatemanEDCost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United KingdomEur J Health Econ2014151698223392624
- Rutten-van MölkenMPOostenbrinkJBMiravitllesMMonzBUModelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in SpainEur J Health Econ20078212313517370096
- HedenströmHMalmbergPFridrikssonHVReference values for lung function tests in men: regression equations with smoking variablesUps J Med Sci19869132993103811032
- ForcheGStadloberEHarnoncourtKNeue spirometrische bezugswerte für kinder, jugendliche und erwachsene [New spirometric reference values for children, adolescents and adults]Austrian Physician Journal198843434042 German
- QuanjerPHTammelingGJCotesJEPedersenOFPeslinRYernaultJCLung volumes and forced ventilatory flowsEur Respir J19936Suppl 1654024576915
- RocaJBurgosFSunyerJReferences values for forced spirometryEur Respir J1998116135413629657579
- HankinsonJLOdencrantzJRFedanKBSpirometric reference values from a sample of the general U.S. populationAm J Respir Crit Care Med199915911791879872837
- LanghammerAJohnsenRGulsvikAHolmenTLBjermerLForced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trøndelag studyEur Respir J200118577077911757626
- FalaschettiELaihoJPrimatestaPPurdonSPrediction equations for normal and low lung function from the Health Survey for EnglandEur Respir J200423345646315065839
- Health and Social Care Information CenterHealth Survey for England, 2009: trend tables. Table 2: Mean height, by survey year, age, and sex2010 Available from: http://www.hscic.gov.uk/pubs/hse09trendsAccessed May 13, 2016
- TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
- NHS TaysideRespiratory update – COPDTayside Prescriber2014131 Available from: http://www.nhstaysideadtc.scot.nhs.uk/approved/bulletin/taypres/2014/Tayside%20Prescriber%20131%20-%20Respiratory%20Update%20%20COPD%20April%202014%20final.pdfAccessed May 13, 2016
- NHS Greater Glasgow and ClydeNHS GGC primary care COPD guideline2013 Available from http://library.nhsggc.org.uk/mediaAssets/My%20HSD/COPD%20guidelines.pdfAccessed May 13, 2016
- NHS Forth ValleyGuideline on the management of chronic obstructive pulmonary disease: version 2 2012 Available from: http://www.nhsforthvalley.com/__documents/qi/ce_guideline_copd/nhsfvcopd-guideline.pdfAccessed October 3, 2014
- NHS FifeCOPD resource pack – section 5: Drug treatment & inhalers in stable COPD 2013 [cited 2014 Dec]. Available from: http://publications.1fife.org.uk/weborgs/nhs/uploadfiles/publications/c64_Section5-DrugTreatmentInhalersinStableCOPD-2014pdfAccessed May 13, 2016
- OostenbrinkJBRutten-van MölkenMPMonzBUFitzGeraldJMProbabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countriesValue Health200581324615841892
- CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
- BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax200358539940412728159
- VinckenWvan NoordJAGreefhorstAPImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J200219220921611871363
- MillerDKHomanSMDetermining transition probabilities: confusion and suggestionsMed Decis Making199414152588152357
- BoutouAKShrikrishnaDTannerRJLung function indices for predicting mortality in COPDEur Respir J201342361662523349449
- Royal Pharmaceutical SocietyBritish National FormularyLondonPharmaceutical Press 2014 Available from: http://www.bnf.org/products/bnf-onlineAccessed May 13, 2016
- Personal Social Services Research UnitUnit Costs of Health & Social Care 2013Canterbury, UKPSSRU2013
- Department of HealthNHS Reference Costs 2012 to 2013LondonDepartment of Health2013 Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013Accessed May 13, 2016
- Organisation for Economic Co-operation and DevelopmentStatistics Directorate Available from: http://www.oecd.org/stdAccessed May 13, 2016
- ISD ScotlandScottish National Tariff 2013/14EdinburghISD2013 Available from: http://www.isdscotland.org/Health-Topics/Finance/Scottish-National-TariffAccessed May 13, 2016
- Rutten-van MölkenMPOostenbrinkJBTashkinDPBurkhartDMonzBUDoes quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?Chest200613041117112817035446
- SpencerMBriggsAHGrossmanRFRanceLDevelopment of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary diseasePharmacoeconomics200523661963715960557
- PatersonCLanganCEMcKaigGAAssessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D)Qual Life Res20009552152711190007
- BriggsASculpherMClaxtonKDecision Modelling for Health Economic EvaluationOxford, UKOxford University Press2006
- StarkieHJBriggsAHChambersMGJonesPPredicting EQ-5D values using the SGRQValue Health201114235436021402304
- CaroJJBriggsASiebertUKuntzKMModeling good research practices – overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1Value Health201215679680322999128
- National Collaborating Centre for Chronic ConditionsHypertension: Management in Adults in Primary Care – Pharmacological UpdateLondonRoyal College of Physicians 2006 Available from: http://www.ncbi.nlm.nih.gov/books/NBK45886/pdf/Bookshelf_NBK45886.pdfAccessed May 13, 2016
- Canadian Agency for Drugs and Technologies in HealthThiazide Diuretics as First-Line Treatment for Hypertension: Meta-analysis and Economic EvaluationOttawaCADTH 2007 Available from: https://www.cadth.ca/thiazide-diuretics-first-line-treatment-hypertension-meta-analysis-and-economic-evaluation-0Accessed May 13, 2016
- HoogendoornMRutten-van MölkenMHoogenveenRMaiwennAFeenstraTComparing the cost-effectiveness of a wide range of COPD interventions using a stochastic, dynamic, population model for COPD Available from http://repub.eur.nl/pub/20172/Comparing%20the%20cost-effectiveness%20of%20a%20wide%20range%20of%20COPD.pdf2010Accessed May 30, 2016